Tumour rejection Antigen P815 (35-43)

Tumour rejection Antigen P815 (35-43) is a synthetic peptide fragment derived from the P815 tumor-associated antigen, specifically encompassing amino acid residues 35 to 43 of the parent protein. As a defined peptide epitope, it is recognized for its role in immunological studies focused on tumor antigenicity and T-cell mediated immune responses. Its well-characterized sequence and immunogenic properties make it a valuable model system for investigating mechanisms of antigen processing, presentation, and the cellular immune response in cancer research. The availability of this peptide enables researchers to conduct targeted studies on antigen-specific recognition, facilitating a deeper understanding of host defenses against tumor cells at the molecular level.

Immunological Research: Utilization of the P815 (35-43) peptide is fundamental in the study of antigen-specific T-cell responses. Researchers employ this epitope to stimulate and monitor cytotoxic T lymphocyte (CTL) activity, allowing for precise assessment of immune recognition and effector functions against tumor antigens. The peptide's defined sequence enables the dissection of MHC class I-restricted antigen presentation pathways, supporting investigations into the molecular basis of immune surveillance and tumor rejection.

Vaccine Design and Evaluation: The P815 (35-43) peptide serves as a prototypical model in preclinical vaccine development, particularly for peptide-based cancer immunotherapies. By incorporating this epitope into experimental vaccine formulations, scientists can evaluate immunogenicity, optimize adjuvant combinations, and refine delivery strategies. Its use in immunization protocols provides critical insights into the induction of robust, antigen-specific cellular immune responses, informing the rational design of next-generation tumor vaccines.

Epitope Mapping and T-Cell Receptor Specificity: The defined nature of the P815 (35-43) peptide supports advanced studies in epitope mapping and T-cell receptor (TCR) specificity. Researchers utilize the peptide to characterize the fine specificity of TCRs, analyze cross-reactivity, and delineate the structural determinants of antigen recognition. These investigations are essential for understanding T-cell repertoire diversity and for engineering TCRs with enhanced specificity for adoptive cell transfer applications.

Antigen Processing and Presentation Assays: The P815 (35-43) sequence is widely used in in vitro assays to investigate the intracellular processing and presentation of peptide antigens by major histocompatibility complex (MHC) molecules. By tracking the fate of the peptide in antigen-presenting cells, scientists can elucidate the mechanisms governing peptide loading, stability, and presentation efficiency. Such studies contribute to a comprehensive understanding of the molecular interactions that underpin effective anti-tumor immune responses.

Peptide-Based Functional Studies: Beyond its immunological applications, the P815 (35-43) peptide is employed in a range of functional assays to probe peptide-MHC binding affinities, study peptide stability in biological matrices, and assess the impact of sequence modifications on immunogenicity. These investigations are instrumental in optimizing peptide selection for research and development purposes, supporting the advancement of peptide-based technologies in cancer immunology and related fields.

1. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

2. TMEM16F and dynamins control expansive plasma membrane reservoirs

3. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

4. Tachykinin-related peptides modulate immune-gene expression in the mealworm beetle Tenebrio molitor L

5. Implications of ligand-receptor binding kinetics on GLP-1R signalling